COMMUNIQUÉS West-GlobeNewswire

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a [...]
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
27/01/2026
ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve [...]
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
27/01/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p- [...]
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
27/01/2026
VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody [...]
Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverage Distribution Across Canada Through Walmart Canada and McKesson Canada
27/01/2026
WESTBROOK, Maine, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced a major expansion of its FOCUSfactor ® [...]
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
27/01/2026
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas [...]
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned
27/01/2026
Tablo becomes first dialysis system to clear FDA’s most rigorous cybersecurity standards SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a [...]
Acentra Health Appoints Balajee Sethuraman as Executive Vice President and Chief Business Services Officer
27/01/2026
Seasoned healthcare and technology leader to oversee business services and delivery operations MCLEAN, Va., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health solutions company dedicated to [...]
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
27/01/2026
Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow [...]
NewGen to Execute Up to US$2 Million Share Repurchase Program Through Benchmark
27/01/2026
Management reiterates strong confidence in NewGen’s long-term fundamentals and disciplined capital allocation strategy BANGKOK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “ [...]
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
27/01/2026
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate Self- [...]
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
27/01/2026
Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc [...]
Evosep Launches IQ/OQ Protocols for the Evosep Eno System at WCBP 2026
27/01/2026
Washington, D.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- WCBP -- Evosep is proud to announce a major advancement in quality assurance for pharmaceutical and regulated laboratories with the introduction of Installation [...]
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
27/01/2026
“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, [...]
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma
27/01/2026
BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has [...]
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
27/01/2026
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a [...]
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
27/01/2026
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial [...]
SRx Health Solutions Allocates Further Capital to its Digital Asset Treasury Hedging Strategy, Bringing Total Allocation to $18 Million
27/01/2026
NORTH PALM BEACH, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced allocating further capital to its digital treasury management strategy with the [...]

Pages